REVIEW ARTICLE

Emerging Role of Artificial Intelligence In Alzheimer's Biomarker Identification and Drug Development

Bhanu N[1], K. Kavitha[1*], Jancy K S[1], Swapna K Y[1], Sangeetha N[1], Saikonda Sree Nikitha[1]

[1] Department of Pharmaceutics, Nitte College of Pharmaceutical Sciences (Nitte Deemed to be University), Bengaluru, Karnataka, India - 560064

***Corresponding Author:** K. Kavitha, Department of Pharmaceutics, Nitte College of Pharmaceutical Sciences, Nitte (Deemed to be University), Bengaluru, Karnataka, India. Email: kavitha.k@nitte.edu.in

Received: 2nd Mar, 2026 | **Revised:** 14th Mar, 2026 | **Accepted:** 4th Apr, 2026 | **Available Online:** 20th Apr, 2026

ABSTRACT

This paper discusses the transformative opportunities of artificial intelligence (AI) to curb the Alzheimer disease (AD), a leading etiology of dementia that has amyloid-β plaques and tau proteins tangles that trigger cognitive decline. It emphasizes AI-powered solutions, such as early diagnostic protocols based on machine-learning analyses of neuroimaging data and biomarkers; identification of new biomarkers using multi-omics analyses; and faster pharmacological development of drugs using virtual screening and target-identification. The main contributions include AI approaches, including convolutional neural networks (CNNs), support-vector machines (SVMs), and random forest classifiers, that are used to categorize the AD stages accurately and outperform the traditional analytic approaches when used in complex datasets; the manuscript provides a list of over 70 empirical studies, of which recent models are published within five years and achieve up to 99 per cent accuracy on the Alzheimer Disease Neuroimaging Initiative (ADNI) and Open Access Series of Imaging Studies (OASIS) repositories. It considers the existing issues, such as data paucity, lack of model interpretability, and ethical implication, and projects the future directions, especially, the inclusion of explainable AI (XAI) and multimodal data integration into personalized treatment plans, and finally assumes that AI will transform AD management by allowing earlier detection and faster therapeutic evolution.

Keywords: Artificial Intelligence, Alzheimer's Disease, Neuroimaging, Machine Learning, Drug Discovery.

How to cite this article: Bhanu N, Kavitha K, Jancy KS, Swapna KY, Sangeetha N, Nikitha SS. EMERGING ROLE OF ARTIFICIAL INTELLIGENCE IN ALZHEIMER'S BIOMARKER IDENTIFICATION AND DRUG DEVELOPMENT. Int J Drug Deliv Technol. 2026;16(33s):566-573. DOI: 10.25258/ijddt.16.33s.68

Source of support: Nil.

Conflict of interest: The authors declare no conflict of interest.

1. INTRODUCTION

AD as it is commonly known is a progressive brain disorder that erodes on itself and your daily functions the longer you live. It is the major cause of dementia in the elderly and a massive health challenge in the world.[1] In essence, it is more than ever before due to the people living longer and more cases over the decades are being seen.[2] According to the World Health Organization (WHO), there are millions of people with dementia all over the globe and Alzheimer is nearly two-thirds of these. [3]

The illness kills in your brain beginning with those forsaken β-amyloid plaques outside neurons and the tau tangles inside neurons.[4] Such alterations destroy brain cells, disturb synapses and lead to brain degeneration. The symptoms are first experienced several years before you see anything and this makes early diagnosis to be a real nightmare.[5]

To address this, physicians use neuropsych assessments, imaging such as Positron emission tomography(PET) and magnetic resonance imaging (MRI) scans and cerebrospinal fluid biomarkers.[6] MRI and PET aided in the detection of the changes in the brain structure and functioning.[7] Other possible biomarkers that researchers seek to use to identify the disease at an early stage include β-2 amyloid and tau[8] but these types of tests are not only costly but also slow and in certain cases invasive.[9]

AI is an upcoming trend in bio-research that is making the waves.[10] AI is simply computer systems, which can perform human-like tasks, including pattern recognition, decision making and predictive analytics.[11] In AI, Machine learning (ML) enables firms to make computers learn without writing hard code [12] and Deep learning (DL) moves this a step further by using multi-layer neural networks which identify complex patterns (Fig 1).[13]

The implementation of AI in health care has gone viral due to large datasets and better computing. Artificial intelligence algorithms wade through massive amounts of clinical records, medical images and genomic data to identify indicators of disease they would have previously been masked by standard approaches. Another field where AI finds application in neurology is the analysis of the brain of Alzheimer, Parkinson, Huntington, etc.[14]

Recent studies have demonstrated that ML has the ability to interpret neuroimaging to identify early brain changes in Alzheimer. CNN and other deep learning models have nailing accuracy in the detection of Alzheimer based on MRI and PET data.[15] They are even able to predict the transition between mild impaired cognitive to full Alzheimer, which is crucial to take early measures.[16] The major artificial intelligence techniques applied in Alzheimer's research, along with their corresponding data types and outcomes, are summarized in Table 1.

Another area where AI is excelling is biomarker discovery and drug development advancement.[17] To identify novel disease-related biomarkers, AI tools can be applied to multi-omics data, which combines genomics, proteomics and metabolomics data.[18] Besides, the MLs are trending in drug discovery, identifying therapeutic targets and accelerating new drug development.[19]

Nevertheless, even with all these advances, there is yet to develop concrete treatments of Alzheimer. Numerous experiments against β-amyloid and tau have been fruitless. It demonstrates that we should have new research conceptions in order to understand the disease better and develop new treatment.

The AI presents hopeful methods of overcoming some of the previous research constraints.[20] The combination of various biomedical datasets and smart computer models can enable AI to substantially enhance the detection of diseases at an early stage, biomarker identification and drug development. Accordingly, the aim of this review is to describe how AI is taking over in Alzheimer-related research, particularly biomarker discovery and catalyzing drug discovery.

Table 1: AI Models Used in Alzheimer's Research

AI Technique	Data Type	Outcome
CNN	MRI	Disease prediction
Deep learning	Imaging	Early detection
Neural networks	Neuroimaging	Disease classification
Random forest	Clinical data	Risk prediction
Machine learning	Biomarker data	Biomarker identification

2. AI in Drug Discovery

The discovery and testing of effective therapeutic agents to treat Alzheimer disease is yet to be accomplished with a lot of difficulty, owing to the complexity and multifactorial pathology of the disorder. The traditional drug discovery processes are often lengthy, expensive and associated with a high rate of failure during the clinical testing.AI has emerged as a promising initiative in the recent past to accelerate the drug discovery process and has enabled faster screening of large chemical and biological libraries.[21] The artificial intelligence frameworks are increasingly being used to identify future therapeutic targets that are involved in the pathogenesis of Alzheimer's disease. Controlled and uncontrolled machine learning algorithms explain genomic, proteomic and transcriptomic data, thus identifying genes and molecular mechanisms that are associated with disease advancement.[22] These types of computational insights allow the researcher to prioritize druggable targets and better understand the pathophysiological processes that cause Alzheimer disease.[23]

The second relevant use of AI in drug discovery is to do virtual screening of chemical entities. AI models evaluate thousands to millions of compounds in chemical databases, which predict their future effects on biological activity on specified drug targets. This ability essentially limits the time and financial resources required to identify promising drug candidates in comparison to the traditional high-throughput screening procedures.

Artificial intelligence is also widely used in the context of drug repurposing, which is a strategy of discovering new therapeutic uses of existing pharmacological drugs. Machine learning algorithms query large biomedical data to predict potential drug-disease interactions between drugs and disease-related targets. Several studies have confirmed that the repurposing approaches guided by AI have been effective in nominating the currently available compounds that have a plausible therapeutic effectiveness against Alzheimer disease.[24] A comparative overview of traditional drug discovery and AI-based approaches is presented in Table 2.

TABLE 2: Comparison of Traditional vs AI-Based Drug Discovery

FEATURE	Traditional drug discovery	AI-Based drug discovery
Time required	10-15 years	3-6 years
Cost	Very high	Reduced
Compound screening	Laboratory testing	Virtual screening
Success rate	Low	Improved prediction
Data analysis	Manual	Automated

Moreover, deep learning models are being used more often to forecast pharmacokinetic and pharmacodynamic characteristics of pharmaceutical entities including absorption, distribution, metabolism and toxicity.[25] These predictive models are used to optimize drug candidates at the beginning of drug development and increase the success rates of clinical trials.[26] On the whole, artificial intelligence has the potential to revolutionize the drug discovery of

Alzheimer, which is by speeding up the detection of therapeutic targets, simplifying the search of chemical compounds and improving the forecast of drug characteristics. Such advances within methodology can significantly enhance the process of creating effective treatments of the Alzheimer disease in future.

3. Artificial Intelligence in Alzheimer's Disease

AI has become a strategic technological tool in the diagnosis and treatment of Alzheimer. AI is a collection of computational procedures that can analyze vast amounts of data and detect complex trends that would otherwise go undetected by other statistical tools.[27] Over the past few years, AI has had widespread application in neurological studies in order to enhance the diagnosis, prognosis and treatment of neurodegenerative diseases, such as Alzheimer disease.[28]

Machine learning is one of the key areas of AI, which enables computers to learn using data and produce predictions without any explicit programming.[29] A wide variety of machine-learning algorithms have been effectively utilized to examine clinical and neuroimaging data that are relevant to Alzheimer's disease.[30] These algorithms are able to categorise patients into specific disease categories such as healthy individuals, mild cognitive impairment and Alzheimer disease with a great degree of accuracy.[31]

Convolutional Neural Networks(CNN) and other deep learning methods have shown excellent results when used on neuroimaging data, including MRI scans and PET scans.[32] These models are automatic ways of extracting salient features of the brain images and detecting structural changes that are related to the pathology of Alzheimer.[33] Evidence suggests that the AI-driven models are also capable of identifying minor brain anomalies several years before clinical manifestation.[34]

In addition, AI systems continue to combine various data sources such as imaging, genetic and clinical data to better predict diseases and assess the risk.[35] The integrative approaches have the potential of enhancing early diagnosis and individualized treatment plans of patients with Alzheimer disease.[36]

4. Machine Learning Techniques Used in Alzheimer's Research

ML is one of the most widely utilized paradigms in the field of artificial intelligence in the analysis of biomedical data and predicting the outcomes of diseases. Applicable in the case of Alzheimer disease, the ML techniques are used to query the large datasets obtained by neuroimaging, genomics, clinical records and cognitive assessments.[37] Such methods make it easier to identify trends related to the development and evolution of diseases that would otherwise be missed in traditional statistical practices.

The major Machine learning techniques applied in the Alzheimer's Disease research are illustrated in figure 1. The SVM, a training algorithm, is commonly used in classifying the diseases. SVM can act on high-dimensional data that is classified into the diagnostic categories: healthy controls, mild cognitive impairment and Alzheimer disease patients. Research indicates that SVM models achieve high diagnostic accuracy in cases where they are used on magnetic resonance imaging and biomarkers datasets.[38] Another common method is the Random forest algorithm an ensemble learning algorithm that is based on multiple decision trees. Random forest models have a pronounced benefit in complex biomedical data since they can take large numbers of variables and identify significant predictive variables. Random forest algorithms have been applied to clinical data in the research of Alzheimer, to isolate biomarkers associated with disease progression.[39] Another area in which Artificial Neural Networks (ANNs) are involved in the study of Alzheimer disease is evident. Based on the design of the human brain, these systems consist of interrelation processing units or neurons that can learn complex nonlinear relationships between variables making them convenient in analyzing biomedical data.[40] CNNs and other types of deep learning have proven to excel in neuro-imaging data analysis and identify structural brain changes related to the presence of Alzheimer's disease. [41]

Another type of ML, which is particularly relevant to the Alzheimer-related research, are Recurrent Neural Networks (RNNs), which apply to the sequential data (specifically, longitudinal cognitive test and patient health history). RNNs are capable of capturing the time dynamics in the data, which allows them to predict the development of a disease with time.[42] Transformer-based deep learning architectures have recently been applied to the biomedical research. These models have the ability to process large volumes of multimodal data and combine data of different sources, such as imaging, genetic and clinical data.[43] It is expected that the use of transformer-based structures will further increase the accuracy of AI-based diagnostic systems of Alzheimer disease.[44]



Figure 1: Major machine learning methods applied in the research on the Alzheimer disease.

5. Biomarkers used in Alzheimer's disease

AI-Based Biomarker Identification

Neuroimaging Biomarkers

The use of AI to analyse neuroimaging data has proven to be incredibly successful in identifying early changes caused by AD. Deep learning models applied to structural MRI can detect hippocampal atrophy, cortical thinning and ventricular enlargement with high sensitivity.[45-46] Amyloid and tau PET imaging analyzed with AI can be used to automatically measure the pathological burden and disease staging.[47]

Longitudinal AI models have been shown to convert mild cognitive impairment (MCI) to Alzheimer disease years before clinical diagnosis, providing useful tools to enable early intervention and enrich clinical trials.[48]

Omics-Based Biomarkers

The integration of genomics, transcriptomics, proteomics and metabolomics data has accelerated the identification of novel AD biomarkers. Machine learning-based multi-omics approaches uncover dysregulated molecular networks associated with amyloid processing, immune activation and synaptic dysfunction.[49-50] Network-based AI models further prioritize key driver genes and pathways implicated in disease progression.

The combination of genomics, transcriptomics, proteomics and metabolomics data has enhanced the discovery of new AD biomarkers. Multi omics methods using machine learning reveal the dysregulated molecular networks related to amyloid processing, immune activation, and synaptic dysfunction. [49-50] Network based AI models also highlight key driver genes and pathways that drive disease progression.

Digital and Behavioural Biomarkers

With the use of speech recognition and typing, gait and wearable sensors, digital biomarkers can be continuously used to assess the cognitive and functional decline of Alzheimer disease on a large scale, with AI algorithms complementing the existing biomarkers. [51]

The key biomarkers used in Alzheimer's disease diagnosis, along with their sources and clinical significance, are summarized in Table 3. These biomarkers, including amyloid-β, tau protein and neurofilament light chain, play a crucial role in early detection, disease monitoring, and understanding disease progression.

TABLE 3: Biomarkers Used in Alzheimer's Disease Diagnosis

Biomarker	Source	Clinical significance
Amyloid-β	CSF / PET imaging	Indicates amyloid plaque deposition
Tau protein	CSF	Reflects neuronal damage
Phosphorylated tau	CSF	Early marker of Alzheimer's pathology
Neurofilament light chain	Blood / CSF	Marker of neurodegeneration
MRI brain atrophy	Imaging	Structural changes in brain

6. Challenges and Limitations

Although this has gone a long way in ensuring that artificial intelligence is applied in the research of Alzheimer disease, there are still a number of challenges and limitations. Availability of high quality and well annotated datasets used to train machine learning models is one of the biggest challenges. Most AI algorithms need high amounts of data to be highly predictive. Nevertheless, the clinical data concerning the Alzheimer disease is typically scarce, heterogenous, and gathered depending on various protocols, which may impact the accuracy of AI-based models.[52]

The second weakness is that complex machine learning models, especially, deep learning algorithms are not interpretable. Although these models may have high levels of diagnostic accuracy, they tend to act as black boxes whereby it is hard to comprehend their method of coming up with the predictions.[53] This professional non-disclosure can decrease the trust of medical workers in the implementation of AI-based systems in clinical practice.[54]

There are also data privacy and ethical issues that are crucial challenges of artificial intelligence in healthcare. The research on Alzheimer disease processes can be associated with sensitive patient data, such as medical histories and genetic data, neuroimaging studies. The first one is to ensure effective data protection and patient confidentiality when AI-based systems are used.[55]

The imbalanced or non-representative datasets also pose another limitation in the fact that machine learning models may be biased. Unless the AI algorithms are trained on datasets that are representative of diverse populations, the produced models could make inaccurate predictions concerning some groups of patients.[56] This problem underscores the significance of utilizing a variety of and balanced datasets in the research of AI.

Moreover, the introduction of AI technologies in clinical processes is a complicated task. Several medical facilities might not have the technical capacity, computing capabilities and skilled staffs to install high-end AI systems.[57] Besides that, AI-based diagnostic tools are required to be approved by regulators and certified so that they can be used extensively in clinical practice. Thus, these issues need to be tackled to enhance the effective transfer of the artificial intelligence technologies to the real world clinical medicine of managing the Alzheimer disease.

7. Future Perspectives

It can be expected that artificial intelligence will play an increasingly important role in research and clinical management of Alzheimer disease. The rapid development of computational technologies, the spread of massive biomedical data, and further improvements of machine learning algorithms are likely to enhance the performance of AI-based diagnostic systems in terms of accuracy and reliability.[58] These advances promise to allow the earlier detection of the Alzheimer disease, making it a condition necessary to any effective management of the disease and treatment intervention.

One of the most promising future research directions is the combination of multimodal data of neuroimaging, genomic, proteomic, and clinical data. Combination of these mixed data streams can provide an overall explanation of pathophysiology and improve the discovery of resilient biomarkers to diagnose diseases at the earliest stage.[59] AI models with the ability to question such complicated data sets can be used to help identify previously unknown biological pathways that can be involved in the development of the Alzheimer disease.

Another urgent area of growth is the optimization of the explainable artificial intelligence (XAI). The expected future AI systems are expected to provide increased transparency and interpretability, thus allowing the clinicians to understand the rationale behind the diagnostic prediction. These features will probably increase the faith in AI technologies and make their usage in clinical decisions much easier.[60]

In the case of Alzheimer disease, the field of drug discovery and personalized medicine is also going to be redefined radically by artificial intelligence. The models based on AI can be used to discover new therapeutic targets, develop new drug molecules, and predict individual patient treatment reactions. Such competencies can potentially support the development of individual therapeutic plans, which are specific to genetic and clinical characteristics of individual patients.[61]

Also, collaborative partnerships between researchers, clinicians, drug companies and technology companies will be invaluable in the development of AI-based approaches to the research of Alzheimer disease. As long as technological advancement does not slack, and interdisciplinary teamwork is maintained, in the future years, artificial intelligence has the potential of transforming how the diagnosis, treatment, and prevention of Alzheimer disease are carried out.

8. Conclusion

Alzheimer disease remains one of the most critical issues in the neurodegenerative disorders with millions of people around the world being impacted. Prompt diagnosis and development of effective treatment plans cannot be done without in the reduction of the growing burden of this pathology. Conventional diagnostic systems and the pharmaceutical development process are often limited by the complexity of pathophysiology of Alzheimer disease and the large amount of biological data that is necessary to explain its mechanisms.

The concept of artificial intelligence (AI) has become a highly potent tool that can contribute significant research on Alzheimer disease through the manipulation of vast and complex biomedical data. Deep-learning and machine-learning methodologies have delivered promising results on early disease phenotype detection, analysis of neuroimaging data, and predicting future biomarkers of disease progression.

In addition, they have a high portent of speeding up drug-discovery processes, namely, identifying therapeutic targets, performing virtual screening of chemical entities, predicting drug-target interactions. However, there still exist endemic issues, which include the lack of access to quality datasets, lack of transparency in the advanced AI models, and ethical dilemmas related to patient information privacy. These barriers are the most crucial to overcome in order to ensure the effective adoption of AI into the clinical setting.

Overall, AI has the potential to transform the process of diagnostic testing, biomarker identification, and drug-development pipeline in the context of Alzheimer disease research. The continuous improvement of the computational approach, data fusion, and cross-disciplinary cooperation are expected to expand the role of AI in early identification and the development of effective treatment plans in the coming decades.

References

1. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14(4):535–562. doi:10.1016/j.jalz.2018.02.018
2. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer's disease. *Lancet.* 2021;397(10284):1577–1590. doi:10.1016/S0140-6736(20)32205-4
3. World Health Organization. Dementia fact sheet [Internet]. 2023 [cited 2026 Apr 21]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
4. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer's disease:

Towards clinical implementation. *Lancet Neurol.* 2022;21(1):66–77.

5. Ding Y, Sohn JH. Artificial intelligence in Alzheimer's disease research. *Neurosci Biobehav Rev.* 2023;147:105219. doi:10.1016/j.neubiorev.2023.105219
6. Singh SG, Das D, Barman U. Early Alzheimer's disease detection using machine learning techniques. *Diagnostics (Basel).* 2024;14(16):1759. doi:10.3390/diagnostics14161759
7. Malik I, Iqbal A. Deep learning for Alzheimer's disease prediction: A review. *Diagnostics (Basel).* 2024;14(12):1281. doi:10.3390/diagnostics14121281
8. Winchester LM, Harshfield EL. Artificial intelligence for biomarker discovery in Alzheimer's disease. *Alzheimers Dement.* 2023;19:5860–5871. doi:10.1002/alz.13390
9. Zhang Y, Bi K. Advances in biomarkers for Alzheimer's disease. *Drug Des Devel Ther.* 2024;18:85–102. doi:10.2147/DDDT.S471174
10. Battineni G, Sagaro GG. Machine learning in Alzheimer's disease diagnosis. *JMIR Med Inform.* 2023;11:e23959. doi:10.2196/23959
11. Zhou Y, Hou Y. Artificial intelligence approaches in neurodegenerative diseases. *Front Neurosci.* 2021;15:639399. doi:10.3389/fnins.2021.639399
12. Chen J, Habes M. Deep learning in Alzheimer's disease imaging. *Neuroimage.* 2020;207:116136. doi:10.1016/j.neuroimage.2020.116136
13. Lu D, Popuri K. Multimodal deep learning for Alzheimer disease classification. *Sci Rep.* 2018;8:1–11. doi:10.1038/s41598-018-37769-z
14. Shen D, Wu G, Suk HI. Deep learning in medical image analysis. *Annu Rev Biomed Eng.* 2017;19:221–248. doi:10.1146/annurev-bioeng-071516-044442
15. Rajpurkar P, Hannun AY. Deep learning for chest radiograph diagnosis. *PLoS Med.* 2018;15:e1002686. doi:10.1371/journal.pmed.1002686
16. Miotto R, Wang F. Deep learning for healthcare: Review and future directions. *Brief Bioinform.* 2018;19(6):1236–1246. doi:10.1093/bib/bbx044
17. Beam AL, Kohane IS. Big data and machine learning in healthcare. *JAMA.* 2018;319(13):1317–1318. doi:10.1001/jama.2017.18391
18. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. *Nat Med.* 2019;25(1):44–56. doi:10.1038/s41591-018-0300-7
19. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. *Future Healthc J.* 2019;6(2):94–98. doi:10.7861/futurehosp.6-2-94
20. Russell S, Norvig P. *Artificial intelligence: A modern approach.* 4th ed. Pearson; 2021.
21. Jumper J, Evans R. Highly accurate protein structure prediction with AlphaFold. *Nature.* 2021;596(7873):583–589. doi:10.1038/s41586-021-03819-2
22. Ding Y, Sohn JH, Kawczynski MG, Trivedi H, Harnish R, Jenkins NW, et al. A deep learning model to predict Alzheimer's disease progression using brain MRI. *Radiology.* 2022;303(1):160–169. doi:10.1148/radiol.211584
23. Jo T, Nho K, Saykin AJ. Deep learning in Alzheimer's disease: Diagnostic classification and prognostic prediction using neuroimaging data. *Front Aging Neurosci.* 2019;11:220. doi:10.3389/fnagi.2019.00220
24. Liu M, Cheng D, Yan W. Classification of Alzheimer's disease by combination of convolutional and recurrent neural networks using FDG-PET images. *Front Neuroinform.* 2018;12:35. doi:10.3389/fninf.2018.00035
25. Basaia S, Agosta F, Wagner L, Canu E, Magnani G, Santangelo R, et al. Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks. *Neuroimage Clin.* 2019;21:101645. doi:10.1016/j.nicl.2018.101645
26. Wen J, Thibeau-Sutre E, Diaz-Melo M, Samper-González J, Routier A, Bottani S, et al. Convolutional neural networks for classification of Alzheimer's disease: Overview and reproducible evaluation. *Med Image Anal.* 2020;63:101694. doi:10.1016/j.media.2020.101694
27. Vamathevan J, Clark D. Applications of machine learning in drug discovery. *Nat Rev Drug Discov.* 2019;18(6):463–477. doi:10.1038/s41573-019-0024-5
28. Mak KK, Pichika MR. Artificial intelligence in drug development. *Drug Discov Today.* 2019;24(3):773–780. doi:10.1016/j.drudis.2018.11.014
29. Walters WP, Murcko MA. Assessing the impact of generative AI on drug discovery. *Nat Rev Drug Discov.* 2020;19(8):515–516. doi:10.1038/d41573-020-00048-4
30. Schneider G. Automating drug discovery. *Nat Rev Drug Discov.* 2018;17(2):97–113. doi:10.1038/nrd.2017.232

31. Ekins S, Puhl AC. Exploiting machine learning for drug discovery. *Nat Mater.* 2019;18(5):435–441. doi:10.1038/s41563-019-0338-8
32. Paul D, Sanap G. Artificial intelligence in drug discovery. *Drug Discov Today.* 2021;26(1):80–93. doi:10.1016/j.drudis.2020.10.010
33. Brown DG, Wobst HJ. Opportunities in AI for drug discovery. *Drug Discov Today.* 2020;25(1):187–195. doi:10.1016/j.drudis.2019.10.024
34. Schneider P, Walters WP. Rethinking drug design in the AI era. *Nat Rev Drug Discov.* 2020;19(5):353–364. doi:10.1038/s41573-019-0050-3
35. Chen H, Engkvist O. The rise of deep learning in drug discovery. *Drug Discov Today.* 2018;23(6):1241–1250. doi:10.1016/j.drudis.2018.01.039
36. Zhavoronkov A, Ivanenkov YA. Deep learning enables rapid identification of drug candidates. *Nat Biotechnol.* 2019;37(9):1038–1040. doi:10.1038/s41587-019-0224-x
37. Lundervold AS, Lundervold A. An overview of deep learning in medical imaging focusing on MRI. *Z Med Phys.* 2019;29(2):102–127. doi:10.1016/j.zemedi.2018.11.002
38. Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. *WIREs Data Min Knowl Discov.* 2019;9(4):e1312. doi:10.1002/widm.1312
39. Topol EJ. Artificial intelligence in healthcare: Past, present and future. *Nat Med.* 2019;25(1):44–56. doi:10.1038/s41591-018-0300-7
40. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. *N Engl J Med.* 2019;380(14):1347–1358. doi:10.1056/NEJMra1814259
41. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. *Nat Med.* 2019;25(1):24–29. doi:10.1038/s41591-018-0316-z
42. Haibe-Kains B, Adam GA, Hosny A, Khodakarami F, Waldron L, Wang B, et al. Transparency and reproducibility in artificial intelligence. *Nature.* 2020;586(7829):52–56. doi:10.1038/s41586-020-2766-8
43. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with AI. *BMC Med.* 2019;17:195. doi:10.1186/s12916-019-1426-2
44. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. *Nat Biomed Eng.* 2018;2(10):719–731. doi:10.1038/s41551-018-0305-z
45. Liu M, Cheng D, Yan W. Classification of Alzheimer's disease by combination of convolutional and recurrent neural networks. *IEEE Trans Biomed Eng.* 2018;65(7):1550–1560.
46. Jo T, Nho K, Saykin AJ. Deep learning in Alzheimer's disease: Diagnostic classification and prognostic prediction. *Front Aging Neurosci.* 2019;11:220.
47. Insel PS, Weiner MW, Mackin RS, et al. Determining clinically meaningful decline in preclinical Alzheimer disease. *Neurology.* 2019;93(4):e322–e333.
48. Ding Y, Sohn JH, Kawczynski MG, et al. A deep learning model to predict Alzheimer's disease progression. *Bioinformatics.* 2019;35(20):4089–4095.
49. Kori M, Aydin B, Unal E, et al. Multi-omics machine learning for Alzheimer's disease biomarker discovery. *Bioinformatics.* 2021;37(3):341–348.
50. Wang M, Roussos P, McKenzie A, et al. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability in Alzheimer's disease. *Nat Neurosci.* 2021;24(2):276–289.
51. Dagum P. Digital biomarkers of cognitive function. *NPJ Digit Med.* 2018;1:1–3.
52. Char DS, Shah NH, Magnus D. Implementing machine learning in healthcare. *N Engl J Med.* 2018;378(11):981–983. doi:10.1056/NEJMp1714229
53. London AJ. Artificial intelligence and black-box decision making in healthcare. *Hastings Cent Rep.* 2019;49(5):15–21. doi:10.1002/hast.973
54. Vellido A. The importance of interpretability in machine learning for healthcare. *IEEE Intell Inform Bull.* 2019;20(2):1–7.
55. Price WN, Cohen IG. Privacy in the age of medical big data. *Nat Med.* 2019;25(1):37–43. doi:10.1038/s41591-018-0272-7
56. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage healthcare. *Science.* 2019;366(6464):447–453. doi:10.1126/science.aax2342
57. Reddy S, Allan S, Coghlan S, Cooper P. A governance model for the application of AI in healthcare. *J Am Med Inform Assoc.* 2020;27(3):491–497. doi:10.1093/jamia/ocz192

58. Pesapane F, Codari M, Sardanelli F. Artificial intelligence in medical imaging. *Eur Radiol Exp.* 2018;2:35. doi:10.1186/s41747-018-0061-y
59. Fröhlich H, Balling R, Beerenwinkel N, Kohlbacher O, Kumar S, Lengauer T, et al. From hype to reality: Data science enabling personalized medicine. *BMC Med.* 2018;16:150. doi:10.1186/s12916-018-1122-7
60. Holzinger A. Explainable AI and multi-modal causability in medicine. *Inf Fusion.* 2022;71:57–66. doi:10.1016/j.inffus.2021.01.011
61. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA, et al. Rethinking drug design in the artificial intelligence era. *Nat Rev Drug Discov.* 2020;19(5):353–364. doi:10.1038/s41573-019-0050-x